To investigate inflammatory response and treatment tolerance of long-term infusion of ch14.18/CHO in combination with subcutaneous interleukin-2 in a single center program.
Latest Information Update: 31 May 2019
At a glance
- Drugs Dinutuximab beta (Primary) ; Interleukin-2 (Primary) ; Isotretinoin (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 31 May 2019 New trial record